Galaxy and Celltrion Sign Agreement to Jointly Develop Multi-Specific Antibody-Based Autoimmune Disease Therapies

Shortening Development Timelines and Strengthening Differentiation Strategies

Galaxy, an artificial intelligence (AI)-driven drug discovery company, announced on December 2 that it will collaborate with Celltrion to jointly develop next-generation autoimmune disease therapies based on multi-specific antibodies.

Galaxy

Under this partnership, Galaxy will be responsible for AI-powered antibody design and the initial validation of drug candidates. Celltrion will oversee the entire development process, including preclinical and clinical development as well as commercialization. The collaboration is expected to establish a new drug development model that significantly shortens the timeline from drug candidate discovery to clinical trials and increases the probability of clinical success.

Multi-specific antibodies are gaining attention as next-generation modalities because they can simultaneously regulate multiple targets with a single molecule, thereby controlling the complex immune pathways involved in diseases all at once. However, traditional antibody discovery methods rely on random screening, making it difficult to secure a diverse range of antibodies capable of binding to each target. Moreover, the experimental process of combining these antibodies to derive the optimal multi-specific antibody structure is also highly limited.

Galaxy’s AI-based protein design technology enables the precise molecular-level design of interactions between therapeutic targets and antibodies, allowing the structural characteristics required for optimal therapeutic development to be implemented from the outset. Through its proprietary platform, GalaxyDesign, Galaxy has demonstrated a de novo antibody design success rate of over 30% for multiple targets.

Seok Chaok, CEO of Galaxy, stated, “AI-based protein design technology is transforming the paradigm of drug development-not only by reducing costs and accelerating timelines, but also by enabling the precise implementation of drug candidates with defined structures and functions from the very beginning using AI. This collaboration with Celltrion is especially meaningful as we bring a new development model into real-world industry practice.”

Lee Sooyoung, Head of New Drug Research at Celltrion, commented, “For the development of advanced drugs such as multi-specific antibodies, it is essential to adopt new and diverse approaches that overcome technological limitations. Through our partnership with Galaxy, Celltrion aims to lead the evolving paradigm of drug development and help build a foundation for the continued growth of Korea’s bio-ecosystem.”

This content was produced with the assistance of AI translation services.